174 related articles for article (PubMed ID: 25218607)
1. GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositis.
Coleman EA; Lee JY; Erickson SW; Goodwin JA; Sanathkumar N; Raj VR; Zhou D; McKelvey KD; Apewokin S; Stephens O; Enderlin CA; Vangsted AJ; Reed PJ; Anaissie EJ
Support Care Cancer; 2015 Mar; 23(3):841-9. PubMed ID: 25218607
[TBL] [Abstract][Full Text] [Related]
2. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
[TBL] [Abstract][Full Text] [Related]
3. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Blijlevens N; Schwenkglenks M; Bacon P; D'Addio A; Einsele H; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vokurka S; Quinn B; McCann S;
J Clin Oncol; 2008 Mar; 26(9):1519-25. PubMed ID: 18268357
[TBL] [Abstract][Full Text] [Related]
4. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
5. A single nucleotide polymorphism in SLC7A5 is associated with gastrointestinal toxicity after high-dose melphalan and autologous stem cell transplantation for multiple myeloma.
Giglia JL; White MJ; Hart AJ; Toro JJ; Freytes CO; Holt CC; Cai Y; Williams SM; Brandt SJ
Biol Blood Marrow Transplant; 2014 Jul; 20(7):1014-20. PubMed ID: 24704384
[TBL] [Abstract][Full Text] [Related]
6. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.
Batlle M; Morgades M; Vives S; Ferrà C; Oriol A; Sancho JM; Xicoy B; Moreno M; Magallón L; Ribera JM
Eur J Haematol; 2014 Dec; 93(6):487-91. PubMed ID: 24889275
[TBL] [Abstract][Full Text] [Related]
7. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
[TBL] [Abstract][Full Text] [Related]
8. Use of sidestream dark-field (SDF) imaging for assessing the effects of high-dose melphalan and autologous stem cell transplantation on oral mucosal microcirculation in myeloma patients.
Milstein DM; te Boome LC; Cheung YW; Lindeboom JA; van den Akker HP; Biemond BJ; Ince C
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jan; 109(1):91-7. PubMed ID: 20123381
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of cryotherapy associated with laser therapy for decreasing severity of melphalan-induced oral mucositis during hematological stem-cell transplantation: a prospective clinical study.
de Paula Eduardo F; Bezinelli LM; da Graça Lopes RM; Nascimento Sobrinho JJ; Hamerschlak N; Correa L
Hematol Oncol; 2015 Sep; 33(3):152-8. PubMed ID: 24519448
[TBL] [Abstract][Full Text] [Related]
10. A Single Nucleotide Polymorphism (SNP) in the
Li J; Persaud AK; Johnson JA; Sborov DW; Phelps MA; Hofmeister CC; Poi MJ
Anticancer Res; 2022 Jan; 42(1):385-395. PubMed ID: 34969749
[TBL] [Abstract][Full Text] [Related]
11. The salivary proteome in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients: a labelled and label-free proteomics approach.
van Leeuwen SJM; Proctor GB; Staes A; Laheij AMGA; Potting CMJ; Brennan MT; von Bültzingslöwen I; Rozema FR; Hazenberg MD; Blijlevens NMA; Raber-Durlacher JE; Huysmans MCDNJM
BMC Oral Health; 2023 Jul; 23(1):460. PubMed ID: 37420206
[TBL] [Abstract][Full Text] [Related]
12. Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trial.
Abidi MH; Agarwal R; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Cronin S; Ventimiglia M; Lum L; Zonder J; Ratanatharathorn V; Uberti J
Biol Blood Marrow Transplant; 2012 Sep; 18(9):1455-61. PubMed ID: 22453252
[TBL] [Abstract][Full Text] [Related]
13. Protocol for a randomised controlled trial to study cryoprevention of chemotherapy-induced oral mucositis after autologous stem cell transplantation.
Walladbegi J; Svanberg A; Gellerstedt M
BMJ Open; 2018 Oct; 8(10):e021993. PubMed ID: 30361399
[TBL] [Abstract][Full Text] [Related]
14. Ice-cream used as cryotherapy during high-dose melphalan conditioning reduces oral mucositis after autologous hematopoietic stem cell transplantation.
Jasiński M; Maciejewska M; Brodziak A; Górka M; Skwierawska K; Jędrzejczak WW; Tomaszewska A; Basak GW; Snarski E
Sci Rep; 2021 Nov; 11(1):22507. PubMed ID: 34795377
[TBL] [Abstract][Full Text] [Related]
15. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.
Tosi P; Zamagni E; Ronconi S; Benni M; Motta MR; Rizzi S; Tura S; Cavo M
Leukemia; 2000 Jul; 14(7):1310-3. PubMed ID: 10914557
[TBL] [Abstract][Full Text] [Related]
16. A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function.
Abidi MH; Agarwal R; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Cronin S; Ventimiglia M; Lum L; Ratanatharathorn V; Zonder J; Uberti J
Biol Blood Marrow Transplant; 2013 Jan; 19(1):56-61. PubMed ID: 22892551
[TBL] [Abstract][Full Text] [Related]
17. Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human Mucosa.
Marcussen M; Bødker JS; Christensen HS; Johansen P; Nielsen S; Christiansen I; Bergmann OJ; Bøgsted M; Dybkær K; Vyberg M; Johnsen HE
PLoS One; 2017; 12(1):e0169286. PubMed ID: 28052121
[TBL] [Abstract][Full Text] [Related]
18. Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy.
Rodrigues GH; Jaguar GC; Alves FA; Guollo A; Camandoni VO; Damascena AS; Lima VCC
Lasers Med Sci; 2017 Jul; 32(5):1089-1095. PubMed ID: 28512727
[TBL] [Abstract][Full Text] [Related]
19. Effects of cryotherapy on high-dose melphalan-induced oral mucositis in pediatric patients undergoing autologous stem cell transplantation.
Kawaguchi K; Umeda K; Takachi T; Ogura T; Horikoshi Y; Saida S; Kato I; Hiramatsu H; Adachi S; Takita J; Watanabe K
Pediatr Blood Cancer; 2020 Sep; 67(9):e28495. PubMed ID: 32573946
[TBL] [Abstract][Full Text] [Related]
20. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]